Marinus Pharma (NASDAQ: MRNS) reported Q3 EPS of ($0.61), $0.05 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $7.34 million versus the consensus estimate of $6.28 million.

Guidance:

For the fiscal year 2023, the Company is updating its revenue and operating expense guidance:

The Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million
The Company now expects GAAP operating expenses, inclusive of G&A and R&D, to be in the range of $158 to $162 million, of which the Company expects stock-based compensation to be approximately $16 million; this represents a decrease from the prior guidance range of $160 to $165 million

Expect that cash, cash equivalents, and short-term investments of $176.4 million as of September 30, 2023, will be sufficient to fund the Company’s operating expenses, capital expenditure requirements, and maintain the minimum cash balance of $15 million required under the Company’s debt facility into the fourth quarter of 2024

During the quarter, a total of 3.7 million shares were sold through the Company’s at-the-market (ATM) facility contributing net proceeds of $25.9 million

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.